On Nov 28, major Wall Street analysts update their ratings for $Sarepta Therapeutics (SRPT.US)$, with price targets ranging from $182 to $215.
Morgan Stanley analyst Matthew Harrison maintains with a buy rating, and maintains the target price at $200.
TD Cowen analyst Ritu Baral maintains with a buy rating, and maintains the target price at $203.
Oppenheimer analyst Andreas Argyrides maintains with a buy rating, and maintains the target price at $215.
Piper Sandler analyst Biren Amin maintains with a buy rating, and adjusts the target price from $200 to $182.
Furthermore, according to the comprehensive report, the opinions of $Sarepta Therapeutics (SRPT.US)$'s main analysts recently are as follows:
Following the announcement of Sarepta's agreement with Arrowhead to license several clinical and preclinical programs, an analyst commented positively on the potential enhancement to the company's portfolio. It was noted that this agreement not only strengthens the company's pipeline but also provides potential for additional revenue streams beyond its existing DMD franchise. This strategic move is viewed as a crucial step in diversifying Sarepta's offerings, alleviating investor concerns about reliance on single-event gene therapies.
The collaboration with Arrowhead provides a diversified platform with a definitive long-term investment in chronic strategies for rare diseases, and further diversifies the therapeutic areas through clinical programs addressing muscle, central nervous system, and pulmonary indications. The strategic rationale for this deal complements Sarepta's expertise in rare genetic medicine, and the initiation of a share buyback indicates confidence in near-term revenue prospects.
Here are the latest investment ratings and price targets for $Sarepta Therapeutics (SRPT.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月28日，多家华尔街大行更新了$Sarepta Therapeutics (SRPT.US)$的评级，目标价介于182美元至215美元。
摩根士丹利分析师Matthew Harrison维持买入评级，维持目标价200美元。
TD Cowen分析师Ritu Baral维持买入评级，维持目标价203美元。
奥本海默控股分析师Andreas Argyrides维持买入评级，维持目标价215美元。
派杰投资分析师Biren Amin维持买入评级，并将目标价从200美元下调至182美元。
此外，综合报道，$Sarepta Therapeutics (SRPT.US)$近期主要分析师观点如下：
在Sarepta宣布与Arrowhead达成许可协议，授权多项临床和临床前项目之后，一位分析师对公司组合的潜在增强进行了积极评价。有人指出，该协议不仅加强了公司的产品管线，还为其现有的DMD特许权以外的额外营业收入来源提供了潜力。这一战略举措被视为Sarepta多元化产品的关键一步，减轻了投资者对单一事件基因疗法依赖的担忧。
与Arrowhead的合作为稀有病患者提供了一个多样化的平台，在慢性疾病策略方面进行了明确的长期投资，通过解决肌肉、中枢神经系统和肺部适应症的临床项目进一步使治疗领域多元化。这项交易的战略基础与Sarepta在稀有遗传医学方面的专业知识相辅相成，而股票回购的开始表明对近期营业收入前景的信心。
以下为今日4位分析师对$Sarepta Therapeutics (SRPT.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
